Noninvasive Models to Predict Liver Fibrosis in Patients with Chronic Hepatitis B: A Study from Turkey

Creative Commons License

Korkmaz P., DEMİRTÜRK N., Batirel A., Yardimci A. C., Cagir U., Nemli S. A., ...Daha Fazla

HEPATITIS MONTHLY, cilt.17, sa.12, 2017 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5812/hepatmon.60266
  • Dergi Adı: HEPATITIS MONTHLY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Background: Manynoninvasive methods, including aspartateaminotransaminase (AST)/alanineaminotransaminase (ALT) ratio (AAR), AST-to-platelet ratio index (APRI), Bonacini cirrhosis discriminant score (CDS), fibrosis-4 (FIB4) index, and age-platelet index (API), have been described to determine the stage of hepatic fibrosis. However, thesemethodsare developed for patients with chronic hepatitisC(CHC) andproduce conflicting results in the prediction of liver fibrosis in patients with chronic hepatitis B (CHB).